H.L. Ormond & Company’s Novo Nordisk NVO Stock Holding History

H.L. Ormond & Company’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,650	Closed	-$203K	–	100
2022 Q1	$203K	Buy	+3,650	New	+$187K	0.25%	101

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

H.L. Ormond & Company's NVO Position: Q2 2022 in Review

H.L. Ormond & Company sold out of Novo Nordisk (NVO) in Q2 2022, closing a stake of 3,650 shares — an estimated $203K sold.

H.L. Ormond & Company first reported a position in NVO in Q1 2022 and held it in 1 quarter. The position peaked at $203K in Q1 2022. 933 funds tracked by Wall St. Rank hold NVO as of Q2 2022.

H.L. Ormond & Company reported no remaining Novo Nordisk position as of Q2 2022 after selling out during the quarter.
H.L. Ormond & Company sold 3,650 Novo Nordisk shares in Q2 2022, an estimated $203K.
H.L. Ormond & Company first reported a position in Novo Nordisk in Q1 2022 and held it in 1 quarter.
H.L. Ormond & Company's Novo Nordisk position peaked at $203K in Q1 2022.
933 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2022.

Based on H.L. Ormond & Company's 13F filing for Q2 2022, filed 12 Aug 2022.